文献速递免疫规划慢病防控与筛查

慢性阻塞性肺疾病老年受试者接种异源CoronaVac/ChAdOx-1疫苗后对SARS-CoV-2变异株的中和抗体与T细胞应答

Neutralizing antibody and T-cell responses against SARS-CoV-2 variants by heterologous CoronaVac/ChAdOx-1 vaccination in elderly subjects with chronic obstructive pulmonary disease.
PubMed 文献 · Vaccine · 2023-08-18

本研究在慢性阻塞性肺疾病(COPD)患者中评估异源CoronaVac/ChAdOx-1(CoVac/ChAd)疫苗接种前后针对SARS-CoV-2野生型及关注变异株的中和抗体(NAb)与特异性CD4、CD8 T细胞应答。接种4周后,针对野生型、Alpha、Beta和Delta变异株的NAb抑制率中位数显著高于接种前,针对Omicron的NAb诱导很低;CD4 T细胞亚群应答略有诱导。

要点

  • COPD患者接种异源CoVac/ChAd疫苗4周后,针对野生型、Alpha、Beta、Delta的NAb抑制率中位数显著高于接种前。
  • 针对Omicron的NAb诱导相比其他变异株很低。
  • CD4 T细胞亚群应答略有诱导,对Alpha、Beta、Delta刺突肽的T细胞应答与野生型同源肽无差异。

核心结论

  • 异源CoVac/ChAd疫苗在COPD患者中诱导了针对SARS-CoV-2野生型、Alpha、Beta和Delta变异株的NAb产生,但针对Omicron的NAb诱导很低。
  • 该疫苗方案对CD4 T细胞亚群应答略有诱导。

研究设计与样本

  • 在COPD患者中于接种前后检测针对SARS-CoV-2野生型和关注变异株的NAb水平及特异性CD4和CD8 T细胞应答。
  • 本研究经临床试验注册(研究ID:TCTR20210822002)。

主要发现

  • 接种4周后,针对SARS-CoV-2野生型、Alpha、Beta和Delta变异株的NAb抑制率中位数显著高于接种前。
  • 针对Omicron的NAb诱导相比其他变异株很低。
  • 接种4周后相比接种前,经野生型刺突肽刺激后产生TNF-α、IFN-γ、IL-4、IL-17、IL-10和FasL的CD4 T细胞呈增加趋势。
  • 对Alpha、Beta和Delta变异株刺突肽的T细胞应答与其野生型同源肽相比无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on humoral and cellular immune responses against SARS-CoV-2 after receiving heterologous CoronaVac/ChAdOx-1 (CoVac/ChAd) vaccination in subjects with chronic obstructive pulmonary disease (COPD) are still limited. Therefore, we determined the neutralizing antibody (NAb) and T-cell responses against SARS-CoV-2 wild type (WT) and variants of concern (VOCs) in COPD patients. METHODS: The levels of NAb as well as specific CD4 and CD8 T-cell responses against SARS-CoV-2 WT and VOCs were determined in COPD patients before and after vaccination. RESULTS: Four weeks after vaccinations, the median levels of % inhibition of NAb against SARS-CoV-2 WT, Alpha, Beta, and Delta variants were significantly higher compared to pre-vaccination. The induction of NAb against Omicron was very low compared to other variants. At four weeks after vaccination, in comparison to pre-vaccination, the increasing trend of TNF-α-, IFN-γ-, IL-4-, IL-17-, IL-10-, and FasL-producing CD4 T-cells upon stimulation with WT spike peptides were demonstrated. No difference in T-cell responses to spike peptides of Alpha, Beta, and Delta variants and their WT homologs was observed. CONCLUSION: Heterologous CoVac/ChAd vaccine induced the production of NAb against SARS-CoV-2 WT, Alpha, Beta, and Delta variants, but low for Omicron in COPD patients. Induction of CD4 T-cell subset responses was slightly observed by this vaccine regimen. CLINICAL TRIALS REGISTRY: This study was approved by the Clinical Trials Registry (Study ID: TCTR20210822002).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chaiwong W, Takheaw N, Pata S, et al. Neutralizing antibody and T-cell responses against SARS-CoV-2 variants by heterologous CoronaVac/ChAdOx-1 vaccination in elderly subjects with chronic obstructive pulmonary disease. Vaccine. 2023. PMID: 37599143. doi:10.1016/j.vaccine.2023.08.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。